- Home
- SITC vs HELP Comparison
SITC vs HELP Comparison
Compare SITC & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SITC | HELP |
|---|---|---|
| Founded | 1965 | N/A |
| Country | United States | Canada |
| Employees | 155 | 50 |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 297.5M | 281.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SITC | HELP |
|---|---|---|
| Price | $5.41 | $4.63 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $10.83 | ★ $95.00 |
| AVG Volume (30 Days) | 893.7K | ★ 1.1M |
| Earning Date | 05-06-2026 | 07-01-2026 |
| Dividend Yield | ★ 122.95% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.09 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.35 | $4.52 |
| 52 Week High | $13.27 | $8.55 |
Technical Indicators
Market Signals| Indicator | SITC | HELP |
|---|---|---|
| Relative Strength Index (RSI) | 24.51 | 34.75 |
| Support Level | N/A | $4.52 |
| Resistance Level | $6.57 | $7.28 |
| Average True Range (ATR) | 0.17 | 0.52 |
| MACD | -0.07 | -0.15 |
| Stochastic Oscillator | 5.03 | 2.23 |
Price Performance
Historical ComparisonAbout SITC SITE Centers Corp.
SITE Centers Corp is a self-administered and self-managed REIT that operates as a fully integrated real estate company. The company is engaged in the business of owning, leasing, acquiring, redeveloping, developing, and managing shopping centers.
About HELP Cybin Inc. Common Stock
Helus Pharma Inc is a clinical-stage pharmaceutical company developing proprietary novel serotonergic agonists (NSAs), which are synthetic molecules designed to activate serotonin pathways associated with neuroplasticity. These compounds are being investigated for potential use in the treatment of depression, anxiety, and other mental health conditions, areas where there is an unmet medical need. It aims to provide treatments designed for mental health disorders. The company is currently developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of substantial depressive disorder. It operates in Canada, the United States, the United Kingdom, and Ireland.